Focus Partners Wealth Has $171.53 Million Stock Position in Becton, Dickinson and Company $BDX

Focus Partners Wealth lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 1,566.6% during the fourth quarter, Holdings Channel.com reports. The firm owned 884,056 shares of the medical instruments supplier’s stock after acquiring an additional 831,010 shares during the period. Focus Partners Wealth’s holdings in Becton, Dickinson and Company were worth $171,526,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in BDX. Imprint Wealth LLC acquired a new position in Becton, Dickinson and Company during the 3rd quarter worth approximately $25,000. Steph & Co. boosted its holdings in Becton, Dickinson and Company by 95.6% in the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 65 shares in the last quarter. Accredited Wealth Management LLC boosted its holdings in Becton, Dickinson and Company by 77.8% in the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 70 shares in the last quarter. WPG Advisers LLC boosted its holdings in Becton, Dickinson and Company by 64.2% in the fourth quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 61 shares in the last quarter. Finally, Kohmann Bosshard Financial Services LLC bought a new position in Becton, Dickinson and Company in the fourth quarter worth approximately $32,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $146.13 on Friday. The company has a market cap of $40.27 billion, a PE ratio of 37.00, a price-to-earnings-growth ratio of 10.35 and a beta of 0.22. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The business has a 50 day moving average price of $150.00 and a 200-day moving average price of $174.05. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping the consensus estimate of $2.77 by $0.13. The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the business posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be paid a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.9%. Becton, Dickinson and Company’s dividend payout ratio is 106.33%.

Analyst Ratings Changes

Several brokerages have issued reports on BDX. Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Stifel Nicolaus cut their price target on Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Weiss Ratings lowered Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Barclays increased their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Finally, TD Cowen cut their price target on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a report on Monday, May 4th. Seven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $182.73.

Insider Activity at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $151.48, for a total value of $166,628.00. Following the completion of the sale, the executive vice president directly owned 14,272 shares of the company’s stock, valued at $2,161,922.56. This represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 4,013 shares of company stock valued at $593,434. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.